CD19 and acute lymphoblastic leukemia: Similarly, and consistent with a recent report (23), PRDM1 KO anti-CD19 CAR T-cells better suppressed cancer growth compared to control CAR T-cells in a B-cell acute lymphoblastic leukemia (ALL) model (NALM-6), although these CAR T-cells eventually failed to eradicate tumors (fig.